Table 4.

Notable agent classes not reviewed and prioritized by the TAP committee^*

Agent class	Primary reason for exclusion
MDM2 inhibitors	Target (MDM2 amplification) uncommon
ERBB inhibitors	Target uncommon
Met inhibitor	Target (met amplification) uncommon
Src/Syk inhibitor	Target uncommon
c-Kit inhibitor	Target uncommon
Anti-angiogenic (VEGF and Ang/Tie)	Not sufficiently targeted to define biomarker
Pan-tyrosine kinase inhibitors	Not sufficiently targeted to define biomarker
Aurora kinase inhibitors	Target/biomarker not known
Base excision repair inhibitor (TRC102)	Target/biomarker not known
ATR kinase inhibitor (VX-970)	Target/biomarker not known
FAK inhibitor	Target/biomarker not known
CK2 inhibitors	Target/biomarker not defined by genomic alteration
IGF1R inhibitors	Target/biomarker not defined by genomic alteration

^*TAP = Target and Agent Prioritization committee.